Evommune (EVMN) Assets Average (2025 - 2026)
Evommune (EVMN) reported Assets Average of $273.7 million for Q1 2026, up 76.87% on a QoQ basis from $154.7 million in Q4 2025.
Evommune (EVMN) has 2 years of Assets Average data on file, last reported at $273.7 million in Q1 2026.
- Quarterly Assets Average changed N/A year-over-year to $273.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $273.7 million (changed N/A YoY) and the FY2025 annual result came in at $150.5 million, changed N/A from the prior year.
- Assets Average improved to $273.7 million in Q1 2026 per EVMN's latest filing, from $154.7 million in the prior quarter.
- Across five years, Assets Average topped out at $273.7 million in Q1 2026 and bottomed at $154.7 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 5.05 Bn |
| 10 | Evommune | 782.16 Mn | 570.69 Mn | - | 273.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 273.70 Mn |
| Dec 31, 2025 | 154.75 Mn |